Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer

Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer

Bibliographic Details
Main Authors:	Aman Chaudhary, Ajay Gogia
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Cancer Research, Statistics, and Treatment
Online Access:	http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=796;epage=797;aulast=Chaudhary

Similar Items

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
by: Moulid Hidayat, et al.
Published: (2019-11-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
by: Melissa Bersanelli, et al.
Published: (2014-09-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
by: Jian-Su, et al.
Published: (2011-01-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01)

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
by: Yali Yi, et al.
Published: (2022-03-01)

Evaluation of Efficacy of Gefitinib on Advanced non-small-cell Lung Cancer (NSCLC) Resisted to Chemotherapy
by: Jiangjiang TU, et al.
Published: (2008-04-01)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
by: Zhonghan Zhang, et al.
Published: (2019-12-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
by: Chia-I Shen, et al.
Published: (2021-08-01)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
by: Yali Yi, et al.
Published: (2022-06-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
by: Yuta Nio, et al.
Published: (2022-11-01)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
by: Takuya Araki, et al.
Published: (2012-01-01)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
by: Takuya Araki, et al.
Published: (2012-12-01)

Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
by: Yuhong Jiang, et al.
Published: (2021-04-01)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
by: Nathan T. Bain, et al.
Published: (2022-09-01)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
by: Yahua Wu, et al.
Published: (2023-12-01)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
by: Jing Wang, et al.
Published: (2023-08-01)

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
by: Koichi Goto, et al.
Published: (2023-03-01)

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
by: Ju Lixia, et al.
Published: (2013-02-01)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
by: Tomoaki Sonoda, et al.
Published: (2018-01-01)

Diffuse Lung Metastases in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Subba R. Digumarthy, et al.
Published: (2019-09-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
by: Takuya Araki, et al.
Published: (2013-01-01)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
by: Takuya Araki, et al.
Published: (2013-05-01)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
by: Adèle L’Hostis, et al.
Published: (2023-07-01)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
by: Debby D Wang, et al.
Published: (2015-01-01)

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
by: Takafumi Yorozuya, et al.
Published: (2021-01-01)

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
by: Mari Tone, et al.
Published: (2023-05-01)

EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
by: Antonio Rossi, et al.
Published: (2022-12-01)

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
by: Aakash Desai, et al.
Published: (2024-02-01)